Abstracts tagged "pregnancy"

Abstract Number: 2536 • 2015 ACR/ARHP Annual Meeting
The Role of Race/Ethnicity and SES in Adverse Pregnancy Outcome in SLE and Apl
Sancia Ferguson¹, Elianna Kaplowitz², Laura Trupin³, Edward H. Yelin⁴, Patricia P. Katz^3,5 and Jane E. Salmon⁶, ¹Medicine/Rheumatology, University of California - San Francisco, San Francisco, CA, ²Hospital for Special Surgery, New York, NY, ³Medicine/Rheumatology, University of California San Francisco, San Francisco, CA, ⁴Medicine/Rheumatology, UC San Francisco, San Francisco, CA, ⁵Arthritis Research Group, University of California San Francisco, San Francisco, CA, ⁶Division of Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY
Background/Purpose: Women with Systemic Lupus Erythematosus (SLE) and Anti-Phospholipid Antibodies (aPL) have pregnancies with higher rates of preterm labor, preeclampsia, and fetal loss than healthy…
Abstract Number: 1908 • 2014 ACR/ARHP Annual Meeting
Pregnancy Outcomes in the Tofacitinib RA Safety Database through April 2014
A. Marren¹, Y. Chen¹, D. Frazier² and J. Geier³, ¹Pfizer Inc, Collegeville, PA, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, New York, NY
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Its effect in pregnant women is of interest, as tofacitinib…
Abstract Number: 1877 • 2014 ACR/ARHP Annual Meeting
Pregnancy Outcomes in SLE: Before and after
Elizabeth V. Arkema¹, Kristin Palmsten², Christopher Sjöwall³, Elisabet Svenungsson⁴, Jane E. Salmon⁵ and Julia F Simard⁶, ¹Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ²Pediatrics, University of California, San Diego, La Jolla, CA, ³Deparment of clinical and experimental medicine, Linköping University, Linköping, Sweden, ⁴Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ⁵Rheumatology, Hospital for Special Surgery, New York, NY, ⁶Division of Epidemiology, Health Research and Policy Department, and Division of Immunology & Rheumatology, Department of Medicine, Stanford School of Medicine, Stanford, CA
Background/Purpose: Numerous investigators have demonstrated that the risks of pre-eclampsia, preterm delivery, and fetal death are increased in lupus pregnancies. Adverse events during pregnancy, delivery,…
Abstract Number: 1829 • 2014 ACR/ARHP Annual Meeting
Role of Fluorinated Steroids in Preventing the Progression of Anti-SSA/Ro Associated Isolated Congenital Heart Block to Disease Beyond the Conduction System
Ummara Shah¹, Amit Saxena¹, Sara Sahl², Deborah Friedman³, Jill P. Buyon¹ and Peter M. Izmirly², ¹Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ²Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ³Division of Pediatric Cardiology, New York Medical College, Valhalla, NY
Background/Purpose: The cardiac manifestations of neonatal lupus (cardiac NL) characteristically present as conduction disease. A major concern is the extension of injury beyond the AV…
Abstract Number: 1599 • 2014 ACR/ARHP Annual Meeting
Comparison of Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Pregnancies: Disease Activity, Treatment, and Outcomes
Megan E. B. Clowse, Rheumatology, Duke University Medical Center, Durham, NC
Background/Purpose: While it has long been reported that rheumatoid arthritis (RA) improves with pregnancy, there is very limited information about ankylosing spondylitis (AS) or…
Abstract Number: 1358 • 2014 ACR/ARHP Annual Meeting
A Systematic Analysis of the Safety of Prescribing Anti-Rheumatic Immunosuppressive and Biologic Drugs in Pregnant Women
Sonia Panchal¹, Julia Flint², Maud van de Venne³, Madeline Piper⁴, Alice Hurrel⁵, Joel Cunningham⁵, Mary Gayed⁶, Karen Schreiber⁷, Subha Anthanari⁸, Mohamed Nisar⁸, David Williams⁹, Munther Khamashta¹⁰, Caroline Gordon¹¹ and Ian Giles², ¹Rheumatology, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom, ²UCL Division of Medicine, University College London, London, United Kingdom, ³Obstetrics and Gynaecology, North Bristol NHS Trust, Bristol, United Kingdom, ⁴Ysbyty Ystrad Fawr, Aneurin Bevan Health Board Wales, Wales, United Kingdom, ⁵Institute for Women's Health, University College London, London, United Kingdom, ⁶Rheumatology Division of Infection and Immunity, The Medical School, University of Birmingham, Birmingham, United Kingdom, ⁷Lupus Research Unit, Division of Infection and Immunity, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom, ⁸Rheumatology, Burton Hospitals NHS Foundation Trust, Burton-upon-Trent, United Kingdom, ⁹University College London, London, United Kingdom, ¹⁰Lupus Research Unit, Division of Women's Health, Guy's and St Thomas' NSH Foundation Trust, London, United Kingdom, ¹¹Rheumatology, Division of Infection and Immunity, The Medical School, University of Birmingham, Birmingham, United Kingdom
Background/Purpose The use of anti-rheumatic drugs in pregnancy is often complicated by concerns over their potential for adverse effects. Given that rheumatic diseases often affect…
Abstract Number: 1072 • 2014 ACR/ARHP Annual Meeting
Sex Ratio of Offspring Born to Women with Lupus and Rheumatoid Arthritis
Elizabeth V. Arkema¹, Johan Askling¹, Jane Salmon² and Julia F Simard³, ¹Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Division of Epidemiology, Health Research and Policy Department, and Division of Immunology & Rheumatology, Department of Medicine, Stanford School of Medicine, Stanford, CA
Background/Purpose: Women with SLE are at increased risk for pregnancy complications and specific autoantibodies may result in preferential loss of female offspring. Studies on the…
Abstract Number: 2041 • 2013 ACR/ARHP Annual Meeting
Pregnancy Outcomes In Women Exposed To Golimumab
Amy G. Lau¹, Michael Clark¹, Diane D. Harrison¹, Anja Geldhof², Riikka Nissinen² and Marilyn Sanders¹, ¹Janssen Research & Development, LLC., Horsham, PA, ²Janssen Biologics Europe, Leiden, Netherlands
Background/Purpose: Rheumatologic conditions and inflammatory bowel disease can affect women of childbearing potential. Golimumab (GLM) is approved for rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing…
Abstract Number: 2042 • 2013 ACR/ARHP Annual Meeting
Pregnancy Outcomes In Women With Rheumatologic Conditions Exposed To Infliximab
Sirisha Kalari¹, Fredrik Granath², Chun-Yuan Guo¹, Diane D. Harrison¹, Gabriella Bröms², Anja Geldhof³, Riikka Nissinen³, Marilyn Sanders¹, Mika Gissler⁴, Lars Pedersen⁵, Henrik Toft Sorensen⁵ and Helle Kieler², ¹Janssen Research & Development, LLC., Horsham, PA, ²Centre for Pharmacoepidemiology, Karolinska Institutet, Stockholm, Sweden, ³Janssen Biologics Europe, Leiden, Netherlands, ⁴Information Department, National Institute for Health and Welfare, Helsinki, Finland, ⁵Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: RA, AS, and PsA are approved indications for infliximab (IFX). In the US, IFX is a pregnancy Category B drug. For RA and some…
Abstract Number: 1330 • 2013 ACR/ARHP Annual Meeting
Prednisone Use Associated With Worse Outcomes In Rheumatoid Arthritis Pregnancies
Prateek Chaudhary¹ and M. E. B. Clowse², ¹Division of Rheumatology, Duke University Medical Center, Durham, NC, ²Rheumatology, Duke University Medical Center, Durham, NC
Background/Purpose: Prior reports suggest that disease activity in rheumatoid arthritis (RA) improves in the setting of pregnancy. However, prior studies report half of patients having…
Abstract Number: 1046 • 2013 ACR/ARHP Annual Meeting
Comparison Of The Incidence Of Influenza Like Illness In Pregnant Women With Rheumatoid Arthritis and Women Without Rheumatoid Arthritis Who Receive An Influenza Vaccination
Yunjun Luo¹, Diana L. Johnson², Ronghui Xu³ and Christina D. Chambers¹, ¹Pediatrics, University of California, San Diego, La Jolla, CA, ²University of California San Diego Department of Pediatrics, La Jolla, CA, ³Family and Preventive Medicine, University of California, San Diego, La Jolla, CA
Background/Purpose: Influenza infection poses significant risk to pregnant women, therefore it is recommended that all pregnant women be vaccinated. However, it is unknown whether the…
Abstract Number: 433 • 2013 ACR/ARHP Annual Meeting
Retrospective Analysis Of Certolizumab Pegol Use During Pregnancy: Update Of Impact On Birth Outcomes
Megan E. B. Clowse¹, Douglas C. Wolf², Frauke Förger³, John J. Cush⁴, Christian Stach⁵, Gordana Kosutic⁶, Susan Williams⁶, Chidi Maduka⁶ and Uma Mahadevan⁷, ¹Rheumatology, Duke University Medical Center, Durham, NC, ²Atlanta Gastroenterology Associates, Atlanta, GA, ³Department of Rheumatology and Clinical Immunology and Allergology, Inselspital, University of Bern, Bern, Switzerland, ⁴Baylor Research Institute and Baylor University Medical Center, Dallas, TX, ⁵UCB Pharma, Monheim, Germany, ⁶UCB Pharma, Raleigh, NC, ⁷UCSF Medical Center, San Francisco, CA
Background/Purpose: Certolizumab pegol (CZP) is a PEGylated Fc-free anti-TNF approved in 45 countries for the treatment of rheumatoid arthritis (RA) and/or Crohn's disease (CD). An…
Abstract Number: 2466 • 2012 ACR/ARHP Annual Meeting
Pregnancy Outcome in Women Treated with Adalimumab for the Treatment of Rheumatoid Arthritis: The OTIS Autoimmune Diseases in Pregnancy Project
Christina D. Chambers¹, Diana L. Johnson², Yunjun Luo¹, Janina L. Jimenez¹, Nicole Mirrasoul¹, Elizabeth Salas¹, Kenneth Lyons Jones² and OTIS Research Group³, ¹Pediatrics, University of California, San Diego, La Jolla, CA, ²University of California San Diego Department of Pediatrics, La Jolla, CA, ³Pediatrics, La Jolla
Background/Purpose: The fully human, anti-tumor necrosis factor monoclonal antibody, adalimumab (ADA), is approved for the treatment of rheumatoid arthritis (RA), psoriatic arthritis, ankylosing spondylitis, juvenile…
Abstract Number: 2237 • 2012 ACR/ARHP Annual Meeting
Application and Feasibility of Proposed Systemic Lupus Erythematosus Reproductive Health Care Quality Indicators At a Public Urban Rheumatology Clinic
Itziar Quinzanos¹, Angela Keniston², Joann Zell³, Jinoos Yazdany⁴, Alyssa Nash¹, Rebecca Fransen¹, Jennifer Stichman¹ and Joel M. Hirsh⁵, ¹Dept Medicine, Denver Health Med Ctr, Denver, CO, ²Department of Medicine, Denver Health and Hospital Authority, Denver, CO, ³Medicine, National Jewish Health, Denver, CO, ⁴Medicine, University of California, San Francisco, San Francisco, CA, ⁵Medicine, Division of Rheumatology, Denver Health and Hospital Authority, Denver, CO
Background/Purpose: Reproductive health quality indicators (QIs) for systemic lupus erythematosus (SLE) have recently been developed: anti-ssA, anti-ssB, and phospholipid antibody (aPL) screening prior to pregnancy;…
Abstract Number: 1730 • 2012 ACR/ARHP Annual Meeting
Antiphosphatidylethanolamine Is Not Associated with Thrombosis or Pregnancy Loss in Systemic Lupus Erythematosus
Ehtisham Akhter¹, Hong Fang², Nathalie Bardin³, Marielle San Marco³ and Michelle Petri², ¹Div of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Hopital de la Conception, Marseille, France
Background/Purpose: Phosphatidylethanolamine, a zwitterionic phospholipid, is a major component of the cell plasma membrane. Phospatidylethanolamine exerts both anticoagulant and procoagulant activities in different conditions. The…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].